Publicação

Equity research of novo Nordisk - a shift in focus: from insulin to GLP-1

Ver documento

Detalhes bibliográficos
Resumo:This equity research has the purpose of projecting Novo Nordisk’s operations within the next5 years. There is a growing trend in the company’s focus towards the GLP-1 segment, shifting away from the traditional focus on in sulinglargine. In addition, there is a perception that insulin industry competitors have not suffered a great incidence from the crisis of the pandemic. To evaluate this, we have created a sales-driven financial model for our projections. The end result of as hare price of DKK816.46(10.54% expected return on its current share price)and the sales composition change observed, supports the fore mentioned hypotheses.
Autores principais:Cavalcanti, Eduardo Burguet
Assunto:Valuation Forecasting Health Finance Equity research Health care Insulin Pharmaceutical industry Patents Glp-1 Obesity Pipeline Pharmaceuticals
Ano:2022
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso aberto
Instituição associada:Universidade Nova de Lisboa
Idioma:inglês
Origem:Repositório Institucional da UNL

Registos relacionados

Registos relacionados